In a patient with serum free kappa light chain 19.3 mg/L, serum free lambda light chain 7.7 mg/L, and a kappa/lambda ratio of 2.51, what does this abnormal ratio suggest and what diagnostic work‑up should be performed?

Interpretation of Serum Free Light Chain Results

Direct Interpretation

Your kappa/lambda ratio of 2.51 is abnormal and indicates a monoclonal kappa light chain process that requires immediate hematologic evaluation. 1, 2

The normal reference range for the serum free light chain ratio is 0.26–1.65, and your ratio exceeds this upper limit, signaling a clonal expansion of kappa-producing plasma cells rather than benign polyclonal B-cell activation. 1, 2

---

Essential Diagnostic Workup

Immediate Laboratory Studies

• Serum protein electrophoresis (SPEP) to quantify any monoclonal protein spike that may not be fully captured by free light chains alone 3
• Serum immunofixation electrophoresis (SIFE) because it is more sensitive than SPEP for detecting and typing monoclonal heavy-chain immunoglobulins (IgG, IgA, IgM) 1, 3, 2
• 24-hour urine collection for total protein, urine protein electrophoresis (UPEP), and urine immunofixation electrophoresis (UIFE) to detect urinary monoclonal light chains 4, 3
• Renal function assessment including serum creatinine, estimated glomerular filtration rate (eGFR), and creatinine clearance, because severe renal impairment (CKD stage 5) expands the normal ratio range to approximately 0.34–3.10 1, 2

Baseline Hematologic and Biochemical Panel

• Complete blood count (CBC) with differential and platelet count, plus peripheral blood smear examination for Rouleaux formation 4
• Serum calcium, albumin, lactate dehydrogenase (LDH), and beta-2 microglobulin to assess for CRAB criteria (hyperCalcemia, Renal impairment, Anemia, Bone lesions) and tumor burden 4
• Quantitative immunoglobulins (IgG, IgA, IgM) to evaluate for immunoparesis 4

Bone Marrow and Cytogenetic Studies

• Unilateral bone marrow aspiration and biopsy with immunohistochemistry or flow cytometry to quantify clonal plasma cells (≥10% defines multiple myeloma) and confirm kappa light chain restriction 4
• Fluorescence in situ hybridization (FISH) on purified bone marrow plasma cells to detect high-risk chromosomal abnormalities including del(17p), t(4;14), t(14;16), gain/amp(1q), and del(1p) 4
• Metaphase cytogenetics may provide additional prognostic information 4

Skeletal Imaging

• Low-dose whole-body computed tomography (CT) or whole-body MRI (preferred if available) to identify osteolytic lesions or extramedullary disease 4
• PET/CT can be used as an alternative imaging modality 4

---

Differential Diagnosis Framework

Monoclonal Gammopathies to Consider

1. Light-chain MGUS if all of the following are present: abnormal κ/λ ratio, increased involved (kappa) light chain, absence of monoclonal heavy chain on SPEP/SIFE, <10% bone marrow plasma cells, and no CRAB features 3

2. Multiple myeloma if clonal bone marrow plasma cells ≥10% plus any myeloma-defining event: calcium >11 mg/dL, creatinine >2 mg/dL or eGFR <40 mL/min, hemoglobin <10 g/dL, one or more osteolytic lesions, clonal plasma cells ≥60%, abnormal FLC ratio ≥100 (for kappa), or >1 focal lesion ≥5 mm on MRI 4

3. Light-chain amyloidosis if Congo red–positive tissue deposits are identified in the setting of an abnormal κ/λ ratio 2

4. Smoldering myeloma if serum monoclonal protein ≥3 g/dL or clonal bone marrow plasma cells 10–60% without myeloma-defining events 4

Critical Pitfall to Avoid

Do not assume a polyclonal process based solely on absolute light chain concentrations. Even when both kappa and lambda are elevated in absolute terms, an abnormal ratio definitively indicates monoclonality. 1, 2 Research shows that approximately 25% of lambda-dominant lesions may have falsely normal ratios, but kappa-dominant lesions (like yours) are reliably detected by ratio abnormalities. 5

---

Renal Function Considerations

Assess kidney function immediately because:

• Renal impairment is one of the four myeloma-defining events and carries the greatest impact on overall survival among all CRAB criteria 4
• Light chain cast nephropathy (LCCN) occurs when monoclonal free light chains interact with Tamm-Horsfall protein in the loop of Henle, forming obstructive casts 4
• AKI is rare when serum FLC concentration is <50 mg/dL but increases significantly when concentration exceeds 80–200 mg/dL 4
• Altered renal clearance in CKD stage 5 changes the reference range for κ/λ ratio interpretation 1, 2

---

Follow-Up and Monitoring Strategy

If Monoclonal Protein Is Confirmed (Light-Chain MGUS)

• Low-risk patients: Repeat evaluation at 6 months, then every 2–3 years if stable 1, 3, 2
• Intermediate/high-risk patients: Repeat at 6 months, then annually for life with serum free light chain measurements 1, 3, 2
• Use the same serum free light chain assay (FreeLite or N Latex) for all serial monitoring because results between different platforms are not mathematically interchangeable 3, 2

If Multiple Myeloma Is Diagnosed

• All measurable parameters (both light and heavy chain) must be followed throughout monitoring 3
• Serum free light chains should be followed in addition to SPEP even when serum monoclonal protein is measurable 3
• The serum FLC ratio is required to document stringent complete response according to International Myeloma Working Group criteria 4, 2

---

Key Limitations of the Free Light Chain Assay

• The serum FLC assay does not replace 24-hour urine protein electrophoresis for patients with measurable urinary M-protein 4, 2
• Sensitivity for detecting monoclonal proteins involving both free and heavy-chain-bound light chains is only 72.9% for kappa and 91.4% for lambda when compared to immunofixation electrophoresis 6
• The majority of sera with abnormal immunofixation patterns may have normal κ/λ ratios, underscoring the necessity of performing SIFE in all cases 6

---

Immediate Next Steps

1. Refer to hematology for comprehensive evaluation of a suspected monoclonal kappa light chain disorder 1, 3
2. Complete the diagnostic workup outlined above before the hematology consultation to expedite diagnosis 4
3. Do not delay bone marrow biopsy and FISH testing if clinical or laboratory features suggest active myeloma 4